Koike Hirofumi, Morikawa Minoru, Ishimaru Hideki, Ideguchi Reiko, Uetani Masataka, Miyoshi Mitsuharu
Department of Radiology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Department of Radiology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Diagnostics (Basel). 2023 Feb 28;13(5):914. doi: 10.3390/diagnostics13050914.
Chemical exchange saturation transfer (CEST) is a molecular magnetic resonance imaging (MRI) method that can generate image contrast based on the proton exchange between labeled protons in solutes and free, bulk water protons. Amide proton transfer (APT) imaging is the most frequently reported amide-proton-based CEST technique. It generates image contrast by reflecting the associations of mobile proteins and peptides resonating at 3.5 ppm downfield from water. Although the origin of the APT signal intensity in tumors is unclear, previous studies have suggested that the APT signal intensity is increased in brain tumors due to the increased mobile protein concentrations in malignant cells in association with an increased cellularity. High-grade tumors, which demonstrate a higher proliferation than low-grade tumors, have higher densities and numbers of cells (and higher concentrations of intracellular proteins and peptides) than low-grade tumors. APT-CEST imaging studies suggest that the APT-CEST signal intensity can be used to help differentiate between benign and malignant tumors and high-grade gliomas and low-grade gliomas as well as estimate the nature of lesions. In this review, we summarize the current applications and findings of the APT-CEST imaging of various brain tumors and tumor-like lesions. We report that APT-CEST imaging can provide additional information on intracranial brain tumors and tumor-like lesions compared to the information provided by conventional MRI methods, and that it can help indicate the nature of lesions, differentiate between benign and malignant lesions, and determine therapeutic effects. Future research could initiate or improve the lesion-specific clinical applicability of APT-CEST imaging for meningioma embolization, lipoma, leukoencephalopathy, tuberous sclerosis complex, progressive multifocal leukoencephalopathy, and hippocampal sclerosis.
化学交换饱和转移(CEST)是一种分子磁共振成像(MRI)方法,它可以基于溶质中标记质子与游离的大量水质子之间的质子交换来产生图像对比度。酰胺质子转移(APT)成像是最常报道的基于酰胺质子的CEST技术。它通过反映在水的下游3.5 ppm处共振的可移动蛋白质和肽的缔合来产生图像对比度。尽管肿瘤中APT信号强度的起源尚不清楚,但先前的研究表明,由于恶性细胞中可移动蛋白质浓度的增加以及细胞密度的增加,脑肿瘤中的APT信号强度会升高。高级别肿瘤比低级别肿瘤具有更高的增殖率,其细胞密度和数量(以及细胞内蛋白质和肽的浓度更高)高于低级别肿瘤。APT-CEST成像研究表明,APT-CEST信号强度可用于帮助区分良性和恶性肿瘤、高级别胶质瘤和低级别胶质瘤,以及估计病变的性质。在本综述中,我们总结了各种脑肿瘤和肿瘤样病变的APT-CEST成像的当前应用和研究结果。我们报告称,与传统MRI方法提供的信息相比,APT-CEST成像可以提供有关颅内脑肿瘤和肿瘤样病变的额外信息,并且它可以帮助指示病变的性质、区分良性和恶性病变以及确定治疗效果。未来的研究可以启动或改善APT-CEST成像在脑膜瘤栓塞、脂肪瘤、白质脑病、结节性硬化症、进行性多灶性白质脑病和海马硬化等病变特异性临床应用。